1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/UH3 Clinical Trials Not Allowed) is sponsored by National Human Genome Research Institute (NHGRI). NHGRI aims to establish a research consortium to collaboratively explore the feasibility of developing Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ML/AI Tools to Advance Genomic Translational Research (MAGen) Funded Programs and Projects ML/AI Tools to Advance Genomic Translational Research (MAGen) Contributing NIH Institutes: National Human Genome Research Institute (NHGRI) National Institute on Aging (NIA) Office of Data Science and Strategy (ODSS) The need for increased research to develop tools to translate genomic research findings into clinical applications has been highlighted by NHGRI-convened workshops.
ML/AI techniques have successfully identified novel patterns in non-genomic clinical datasets, receiving FDA approval for ML/AI-enabled medical devices in fields such as radiology, cardiology, and various other disciplines of medicine. Vast amounts of multimodal data are available through advances in FAIR sharing standards and policies, facilitating the potential of using ML/AI approaches in translational genomics.
There is a need to utilize advances in technologies to translate genomic research findings into tools for potential future clinical applications that is we need tools that bridge basic and implementation research referred to in this initiative as, genomics translational research tools developed with disease expert involvement from the design through development and testing.
Maximizing the potential of ML/AI requires thoughtful attention to the ethical, legal, and social implications (ELSI) of its use in genomic medicine and healthcare more broadly. The long-term vision for successful tools would be to test them in clinical implementation settings.
NHGRI aims to establish a research Consortium, ML/AI Tools to Advance Genomic Translational Research (MAGen), to collaboratively explore the feasibility of Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease.
The ML/AI tools will leverage existing multimodal genomic and non-genomic data and will be cross validated in genomic translational research settings to ensure the robustness and generalizability of the tools for translational purposes.
Importantly, the Consortium will explore the ethical, legal, and social implications (ELSI) of integrating ML/AI tools into genomic medicine through the establishment of an ELSI Framework for their development, and through implementation of ELSI research projects.
The Consortium will compose of MAGen Development Sites with multi-disciplinary teams to develop the ML/AI tools and the MAGen Coordinating Center which will be responsible for technical, scientific, and administrative coordination activities to support the Consortium research activities including development of Consortium wide plans, coordinated ELSI-informed ML/AI tool development and cross validation, and dissemination of the developed resources.
From the September 18th, 2023, NHGRI Advisory Council Meeting Concept Clearance Presentation Frequently Asked Questions RFA-HG-24-004 : ML/AI Tools to Advance Genomic translational Research (MAGen) – Development Sites (UG3/UH3, Clinical Trials Not Allowed) Application Due Dates: July 26, 2024| Expiration Date: July 29, 2024 RFA-HG-24-005 : ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/UH3, Clinical Trials Not Allowed) Application Due Dates: July 26, 2024 Expiration Date: July 29, 2024 Related Funding Announcements: Office of Genomic Data Science Division of Genomics and Society Scientific Program Analyst Division of Genome Sciences Division of Neuroscience (DN) Health Data Scientist for AI Ethics Integrated Infrastructure and Emerging Technologies (IIET) Last updated: March 11, 2025
According to the current listing, eligibility includes: Not specified, but generally targets research institutions and small businesses for SBIR/STTR. The UG3/UH3 mechanism is often used for cooperative agreements with research organizations. Confirm the full requirements in the official notice before applying.
ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/UH3 Clinical Trials Not Allowed) is funded by National Human Genome Research Institute (NHGRI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On August 26, 2026, NSF named the STC class of 2026: TEMPEST at Michigan State, GENIE at Northwestern, and a human-robot co-adaptation center at UT Austin. $90 million total, $6 million a year each. The 2023 class was four centers and $120 million. The award size is intact; the shelf space shrank 25 percent — and that is the number that should reshape how you plan a center proposal.
Read articleWhile headlines chase AI and defense money, USDA's National Institute of Food and Agriculture runs a tight summer competitive cycle — Equipment Grants (June 25), Agricultural Genome to Phenome (June 29), New Beginning for Tribal Students (July 2), and Crop Protection and Pest Management (July 6). Here is how the four programs fit together, who is eligible, and why the land-grant system has a structural edge.
Read articleThe STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read article